155 related articles for article (PubMed ID: 30093416)
1. The Importance of Incorporating OCT2 Plasma Membrane Expression and Membrane Potential in IVIVE of Metformin Renal Secretory Clearance.
Kumar V; Yin J; Billington S; Prasad B; Brown CDA; Wang J; Unadkat JD
Drug Metab Dispos; 2018 Oct; 46(10):1441-1445. PubMed ID: 30093416
[TBL] [Abstract][Full Text] [Related]
2. Quantitation of Plasma Membrane Drug Transporters in Kidney Tissue and Cell Lines Using a Novel Proteomic Approach Enabled a Prospective Prediction of Metformin Disposition.
Kikuchi R; Chiou WJ; Durbin KR; Savaryn JP; Ma J; Emami Riedmaier A; de Morais SM; Jenkins GJ; Bow DAJ
Drug Metab Dispos; 2021 Oct; 49(10):938-946. PubMed ID: 34330717
[TBL] [Abstract][Full Text] [Related]
3. Importance of OCT2 and MATE1 for the Cimetidine-Metformin Interaction: Insights from Investigations of Polarized Transport in Single- And Double-Transfected MDCK Cells with a Focus on Perpetrator Disposition.
Müller F; Weitz D; Mertsch K; König J; Fromm MF
Mol Pharm; 2018 Aug; 15(8):3425-3433. PubMed ID: 29975542
[TBL] [Abstract][Full Text] [Related]
4. Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes.
Song IS; Shin HJ; Shin JG
Xenobiotica; 2008 Sep; 38(9):1252-62. PubMed ID: 18728938
[TBL] [Abstract][Full Text] [Related]
5. Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser.
Zolk O; Solbach TF; König J; Fromm MF
Drug Metab Dispos; 2009 Jun; 37(6):1312-8. PubMed ID: 19251820
[TBL] [Abstract][Full Text] [Related]
6. Fampridine is a Substrate and Inhibitor of Human OCT2, but not of Human MATE1, or MATE2K.
Xiao G; Rowbottom C; Boiselle C; Gan LS
Pharm Res; 2018 Jun; 35(8):159. PubMed ID: 29915999
[TBL] [Abstract][Full Text] [Related]
7. Transport Turnover Rates for Human OCT2 and MATE1 Expressed in Chinese Hamster Ovary Cells.
Zhang X; Wright SH
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163393
[TBL] [Abstract][Full Text] [Related]
8. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1.
Kimura N; Masuda S; Tanihara Y; Ueo H; Okuda M; Katsura T; Inui K
Drug Metab Pharmacokinet; 2005 Oct; 20(5):379-86. PubMed ID: 16272756
[TBL] [Abstract][Full Text] [Related]
9. Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects.
Topletz-Erickson AR; Lee AJ; Mayor JG; Rustia EL; Abdulrasool LI; Wise AL; Dailey B; DeChenne S; Walker LN; Alley SC; Endres CJ
J Clin Pharmacol; 2021 Apr; 61(4):461-471. PubMed ID: 32989831
[TBL] [Abstract][Full Text] [Related]
10. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin.
Chen Y; Li S; Brown C; Cheatham S; Castro RA; Leabman MK; Urban TJ; Chen L; Yee SW; Choi JH; Huang Y; Brett CM; Burchard EG; Giacomini KM
Pharmacogenet Genomics; 2009 Jul; 19(7):497-504. PubMed ID: 19483665
[TBL] [Abstract][Full Text] [Related]
11. Contribution of MATE1 to Renal Secretion of the NMDA Receptor Antagonist Memantine.
Müller F; Weitz D; Derdau V; Sandvoss M; Mertsch K; König J; Fromm MF
Mol Pharm; 2017 Sep; 14(9):2991-2998. PubMed ID: 28708400
[TBL] [Abstract][Full Text] [Related]
12. Successful Prediction of Positron Emission Tomography-Imaged Metformin Hepatic Uptake Clearance in Humans Using the Quantitative Proteomics-Informed Relative Expression Factor Approach.
Sachar M; Kumar V; Gormsen LC; Munk OL; Unadkat JD
Drug Metab Dispos; 2020 Nov; 48(11):1210-1216. PubMed ID: 32843330
[TBL] [Abstract][Full Text] [Related]
13. The Effect of Uremic Solutes on the Organic Cation Transporter 2.
Cheung KWK; Hsueh CH; Zhao P; Meyer TW; Zhang L; Huang SM; Giacomini KM
J Pharm Sci; 2017 Sep; 106(9):2551-2557. PubMed ID: 28483424
[TBL] [Abstract][Full Text] [Related]
14. Interaction of beta-blockers with the renal uptake transporter OCT2.
Bachmakov I; Glaeser H; Endress B; Mörl F; König J; Fromm MF
Diabetes Obes Metab; 2009 Nov; 11(11):1080-3. PubMed ID: 19740083
[TBL] [Abstract][Full Text] [Related]
15. Kinetic basis of metformin-MPP interactions with organic cation transporter OCT2.
Sandoval PJ; Morales M; Secomb TW; Wright SH
Am J Physiol Renal Physiol; 2019 Sep; 317(3):F720-F734. PubMed ID: 31313952
[TBL] [Abstract][Full Text] [Related]
16. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
Nishizawa K; Yoda N; Morokado F; Komori H; Nakanishi T; Tamai I
PLoS One; 2019; 14(4):e0214862. PubMed ID: 30951542
[TBL] [Abstract][Full Text] [Related]
17. Substrate-dependent ligand inhibition of the human organic cation transporter OCT2.
Belzer M; Morales M; Jagadish B; Mash EA; Wright SH
J Pharmacol Exp Ther; 2013 Aug; 346(2):300-10. PubMed ID: 23709117
[TBL] [Abstract][Full Text] [Related]
18. Interplay of the Organic Cation Transporters OCT1 and OCT2 with the Apically Localized Export Protein MATE1 for the Polarized Transport of Trospium.
Deutsch B; Neumeister C; Schwantes U; Fromm MF; König J
Mol Pharm; 2019 Feb; 16(2):510-517. PubMed ID: 30656943
[TBL] [Abstract][Full Text] [Related]
19. Incorporating renal excretion via the OCT2 transporter in physiologically based kinetic modelling to predict in vivo kinetics of mepiquat in rat.
Noorlander A; Wesseling S; Rietjens IMCM; van Ravenzwaay B
Toxicol Lett; 2021 Jun; 343():34-43. PubMed ID: 33639197
[TBL] [Abstract][Full Text] [Related]
20. Prediction of the Effects of Renal Impairment on Clearance for Organic Cation Drugs that Undergo Renal Secretion: A Simulation-Based Study.
Follman KE; Morris ME
Drug Metab Dispos; 2018 May; 46(5):758-769. PubMed ID: 29490902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
